<DOC>
	<DOCNO>NCT01029288</DOCNO>
	<brief_summary>The propose trial seek determine impact patient decision aid versus usual care measure patient involvement decision-making , diabetes care process , medication adherence , glycemic cardiovascular risk factor control , resource utilization nonurban practice Midwestern United States . Upon completion trial , investigator new knowledge effectiveness diabetes decision aid nonacademic nonurban practice process promote inhibit successful implementation patient decision aid practice .</brief_summary>
	<brief_title>Impact Decision Aids Enhance Shared Decision Making Diabetes</brief_title>
	<detailed_description>Type 2 diabetes cause loss quality diminish duration life 24 million Americans great cost heavy burden treatment society affect family . Decision aid tool help clinician involve patient make deliberate choice provide accessible information option available outcome . We propose conduct cluster randomize trial obtain estimate impact patient decision aid versus usual care measure patient involvement decision making , diabetes care process , medication adherence , glycemic cardiovascular risk factor control , resource utilization . Participating clinician train use decision aid tool discuss start either new diabetes medication new statin enrol patient . Surveys complete clinician patient assess satisfaction decision make knowledge gain patient . 3- 6-month follow-up survey complete patient assess adherence choose medication sustain knowledge . Primary analysis conduct utilizing generalized linear model . Some visit video and/or audio record permission , small subset patient , clinician , support staff interview experienced qualitative researcher use semi-structured interview guide . Primary care practice enrol matched size ( less equal 2 clinician great 2 clinician ) randomly allocate statistician 1 ) use Diabetes Medication Choice decision aid usual care lipid therapy medication ( statin ) discussion encounter subject 2 ) use Statin Choice decision aid usual care antihyperglycemic mediation discussion encounter subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Primary care provider participate trial Are adult ( â‰¥ 18 year ) type 2 diabetes English speak Recognize primary care provider main diabetes care provider Declare available followup six month treatment decision Have major barrier provide write informed consent participate share decision making ( i.e. , severe vision hearing impairment , cognitive impairment , nonEnglish speaking ) Additional Inclusion Criteria Diabetes Medication : Have clinical diagnosis type 2 diabetes one year ( cpeptide test require ) Use 0 , 1 , 2 oral hypoglycemic agent maximum dos Have stable inadequate glycemic control worsen glycemic control identify recent HbA1c measure ( within 12 month time eligibility 7.3 % Be identify provider medicallyappropriate candidate diabetes medication , ( i.e. , contraindication take medication , e.g. , allergy ) . Additional Exclusion Criteria Diabetes Medication : Use insulin therapy . Additional Inclusion Criteria Cardiovascular Medication : Have clinical diagnosis type 2 diabetes duration ( cpeptide test require ) . Be identify provider medicallyappropriate candidate statin , ( i.e. , contraindication take medication , e.g. , allergy ) . Additional Exclusion Criteria Cardiovascular Medication : Use statin currently .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Decision aid</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Patient education</keyword>
</DOC>